Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 5.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,212,706 shares of the company’s stock after acquiring an additional 64,522 shares during the period. Deutsche Bank AG owned approximately 0.97% of Vaxcyte worth $99,272,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Duquesne Family Office LLC boosted its position in shares of Vaxcyte by 100.8% during the 4th quarter. Duquesne Family Office LLC now owns 86,265 shares of the company’s stock valued at $7,062,000 after purchasing an additional 43,300 shares in the last quarter. Crestline Management LP lifted its stake in Vaxcyte by 88.6% during the fourth quarter. Crestline Management LP now owns 101,035 shares of the company’s stock valued at $8,271,000 after purchasing an additional 47,452 shares during the last quarter. Brevan Howard Capital Management LP boosted its holdings in Vaxcyte by 137.8% during the fourth quarter. Brevan Howard Capital Management LP now owns 4,393 shares of the company’s stock worth $360,000 after buying an additional 2,546 shares in the last quarter. Bridgefront Capital LLC boosted its holdings in Vaxcyte by 4.2% during the fourth quarter. Bridgefront Capital LLC now owns 4,244 shares of the company’s stock worth $347,000 after buying an additional 172 shares in the last quarter. Finally, Brown Advisory Inc. grew its position in Vaxcyte by 25.3% in the fourth quarter. Brown Advisory Inc. now owns 556,209 shares of the company’s stock worth $45,531,000 after buying an additional 112,170 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Insider Activity at Vaxcyte

In related news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total transaction of $670,800.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,180,820.35. This trade represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.10% of the stock is currently owned by insiders.

Vaxcyte Trading Down 0.9%

NASDAQ:PCVX opened at $31.16 on Monday. The business’s fifty day moving average price is $46.66 and its 200 day moving average price is $74.19. The firm has a market capitalization of $4.02 billion, a price-to-earnings ratio of -6.77 and a beta of 1.27. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the prior year, the firm earned ($0.85) earnings per share. Equities analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. The Goldman Sachs Group cut their price objective on Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Bank of America cut their target price on Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Cantor Fitzgerald assumed coverage on Vaxcyte in a research report on Tuesday, April 22nd. They issued an “overweight” rating for the company. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Finally, Guggenheim restated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Vaxcyte has an average rating of “Buy” and an average price target of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.